Stand UP to Rheumatoid Arthritis (SUPRA)
Key facts
- Where
- Montreal, CanadaSee the site
Where in Canada
- Sir Mortimer B Davis - Jewish General HospitalMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Marie Hudson, MD
- Trial code
- NCT05305066
- Record updated
- 3 February 2026
- Original description
Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.Read full original descriptionShow less
Innovative Trial Designs, Multi-omics and Advanced Computational Prediction to Transform Clinical Care in RA
Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.
Inclusion: Age ≥ 18 years; Arthritis that fulfills the 2010 ACR/EULAR classification criteria for RA; Failure to standard conventional synthetic DMARDs and eligible for second-line b/tsDMARDs (Sub-study 1) or failure to at least one TNF inhibitor and eligible for third-line b/tsDMARDs (Sub-study 2).
Exclusion: Prior b/tsDMARDs for Sub-study 1 or prior b/tsDMARDs other than TNF inhibitors for Sub-study 2; Contraindication to b/tsDMARD therapy, such as active infection or untreated latent TB, current malignancy, severe organ dysfunction, history of VTE (unless anticoagulated), high risk of cardiovascular disease, pregnancy/lactation; Overlap with another inflammatory disease requiring specific immunosuppressive therapy, such as lupus nephritis; Unable to provide consent or complete forms (alone or with assistance) in English or French.